We are live on
!
Find out more
WVP
Worth Venture Partners Portfolio holdings
AUM
$31.6M
1-Year Est. Return
28.5%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$15M
AUM Growth
-$170M
(-92%)
Cap. Flow
-$69.6M
Cap. Flow
% of AUM
-462.87%
Top 10 Holdings %
Top 10 Hldgs %
51.84%
Holding
132
New
31
Increased
18
Reduced
10
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$1.45M |
| 2 |
iShares US Medical Devices ETF
IHI
|
+$875K |
| 3 |
Radcom
RDCM
|
+$577K |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$491K |
| 5 |
Insmed
INSM
|
+$431K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Myomo
MYO
|
+$7M |
| 2 |
Aspen Aerogels
ASPN
|
+$6.96M |
| 3 |
indie Semiconductor
INDI
|
+$4.63M |
| 4 |
SCPH
scPharmaceuticals
SCPH
|
+$4.31M |
| 5 |
TGAN
Transphorm, Inc. Common Stock
TGAN
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.82% |
| 2 | Technology | 27.27% |
| 3 | Real Estate | 20.31% |
| 4 | Communication Services | 5.72% |
| 5 | Consumer Staples | 2.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PLYA
26
DELISTED
Playa Hotels & Resorts
PLYA
| $224K | 1.49% |
+23,100
| New | +$204K |
|
27
BioCryst Pharmaceuticals
BCRX
$2.28B
| $198K | 1.32% |
+39,000
| New | +$219K |
|
28
uniQure
QURE
$3.03B
| $178K | 1.19% |
+34,300
| New | +$197K |
|
|
OPRA
29
Opera Ltd
OPRA
$1.69B
| $164K | 1.09% |
10,350
-2,574
| -20% | -$32.5K |
|
30
The GEO Group
GEO
$4.13B
| $150K | 0.99% |
10,590
-60
| -0.6% | -$715 |
|
31
Ceragon Networks
CRNT
$197M
| $149K | 0.99% |
46,596
-40,675
| -47% | -$111K |
|
|
NOTV
32
DELISTED
Inotiv
NOTV
| $148K | 0.99% |
+13,561
| New | +$81.1K |
|
|
33
CALL
Insmed
INSM
$21.4B
| $128K | 0.85% |
+20,500
| New | +$574K |
|
34
Pagaya Technologies
PGY
$1.61B
| $120K | 0.8% |
+11,853
| New | +$168K |
|
35
Fennec Pharmaceuticals
FENC
$332M
| $115K | 0.76% |
10,327
-131,173
| -93% | -$1.32M |
|
|
CTV
36
DELISTED
Innovid Corp.
CTV
| $112K | 0.74% |
+44,825
| New | +$77.6K |
|
|
INFN
37
DELISTED
Infinera Corporation Common Stock
INFN
| $107K | 0.71% |
17,758
+6,508
| +58% | +$32.7K |
|
38
Ribbon Communications
RBBN
$377M
| $95.2K | 0.63% |
29,738
-3,445
| -10% | -$10.5K |
|
39
Marqeta
MQ
$1.83B
| $91.6K | 0.61% |
+3,844
| New | +$95.1K |
|
40
Neuronetics
STIM
$138M
| $80.3K | 0.53% |
16,878
+6,473
| +62% | +$22.7K |
|
41
Mama's Creations
MAMA
$857M
| $78.8K | 0.52% |
15,756
+3,000
| +24% | +$14.2K |
|
42
Lantronix
LTRX
$240M
| $72.7K | 0.48% |
20,414
+7,950
| +64% | +$39K |
|
43
TeraWulf
WULF
$8.75B
| $63.4K | 0.42% |
+24,125
| New | +$47.6K |
|
44
Bit Digital
BTBT
$463M
| $55.9K | 0.37% |
+19,474
| New | +$53.7K |
|
|
AUGX
45
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $55.8K | 0.37% |
13,632
+12
| +0.1% | +$54 |
|
46
Telos
TLS
$332M
| $52K | 0.35% |
+12,500
| New | +$49.5K |
|
47
CALL
Akebia Therapeutics
AKBA
$354M
| $50.1K | 0.33% |
+23,300
| New | +$37.3K |
|
48
Denison Mines
DNN
$2.54B
| $48.8K | 0.32% |
+25,000
| New | +$47.4K |
|
|
KORE
49
DELISTED
KORE Group Holdings
KORE
| $37.1K | 0.25% |
9,420
+2,012
| +27% | +$8.92K |
|
50
PUT
Iovance Biotherapeutics
IOVA
$1.82B
| $25.9K | 0.17% |
+15,500
| New | +$180K |
|
Similar funds
VL
SP
OGC
PE
RL
AIIC
LGM
SCA
Worth Venture Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Worth Venture Partners held 132 positions worth $15M, down 92% from $185M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Worth Venture Partners withdrew a net $69.6M in Q1 2024, closing 70 positions and reducing 10 holdings. Its most notable exit was Myomo, an estimated $7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 21% a quarter earlier, followed by Technology and Real Estate.
Against the trend, Worth Venture Partners opened a new position in Johnson & Johnson worth $1.44M.
- Worth Venture Partners's largest Q1 2024 buy was Johnson & Johnson: 9,100 shares worth $1.44M.
- Worth Venture Partners added most to Arteris in Q1 2024, an estimated $185K increase.
- Worth Venture Partners's biggest Q1 2024 reduction was scPharmaceuticals, cutting an estimated $4.31M.
- Worth Venture Partners fully exited Myomo in Q1 2024, selling an estimated $7M.
- Worth Venture Partners's ten largest holdings make up 52% of its $15M portfolio in Q1 2024.
- Worth Venture Partners opened 31 new positions and closed 70 in Q1 2024.
- Worth Venture Partners's portfolio value fell 92% quarter-over-quarter to $15M.
Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.